News

Cocaine use continues to be a public health problem, yet despite concerted efforts, no drugs have been approved to resolve cocaine addiction. Research suggests that the drug Ritalin® could serve as a cocaine-replacement therapy.

A new study has revealed important associations between the gut microbiome and eczema in infancy, and has established the basis for the potential prevention and treatment of eczema via modulation of the gut microbiota.

Paroxetine is used for the treatment of hot flashes, one of the most reported symptoms among menopausal women and breast cancer survivors. New research suggests that the benefits of the drug could be due to a non-specific placebo response.

A study has revealed a new Australian drug demonstrates potential for treating pancreatic cancer. The drug shows promise for treating pancreatic ductal adenocarcinoma, one of the most aggressive forms of pancreatic cancer.

Of over 100,000 drug overdose deaths reported in the United States in 2021, 71,000 can be attributed to synthetic opioids like fentanyl. Researchers are now getting closer to human trials for vaccines to prevent fentanyl and heroin drug overdoses.

How much time elapses between a blow to the head and the start of damage associated with Alzheimer’s disease? A device that tracks the effects of concussive force on a functioning cluster of brain cells suggests the answer is in hours.

A potential new Alzheimer’s drug represses the harmful inflammatory response of the brain’s immune cells, reducing disease pathology, preserving neurons and improving cognition in preclinical tests.

Osaka Metropolitan University scientists demonstrate the anti-cancer properties of Kencur ginger are caused by its bioactive compound, ethyl p-methoxycinnamate (EMC). In mice, this compound reduced cancer cell proliferation at low doses.

Despite their promised benefits, 40% of breast cancer patients stop taking medication early. A study has found that interventions can increase medication adherence by nearly 1.5 times.

A clinical trial has demonstrated the success of Muvalaplin, the first oral drug ever developed to target Lipoprotein(a), a largely genetic form of cholesterol that increases the risk of heart attack.